Paul Galatsis
Pfizer (United States)(US)
Publications by Year
Research Areas
Asymmetric Synthesis and Catalysis, Synthetic Organic Chemistry Methods, Oxidative Organic Chemistry Reactions, Parkinson's Disease Mechanisms and Treatments, Chemical Synthesis and Analysis
Most-Cited Works
- → Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration(2015)205 cited
- → Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7 H -pyrrolo[2,3- d ]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor(2014)180 cited
- → LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits(2020)126 cited
- → 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol) Inhibits Peroxynitrite-Mediated Phenol Nitration(2000)99 cited
- → Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites(2005)76 cited
- → Phosphoproteomic evaluation of pharmacological inhibition of leucine‐rich repeat kinase 2 reveals significant off‐target effects of LRRK‐2‐IN‐1(2013)66 cited
- → Aqueous intermolecular diels-alder chemistry(1986)64 cited
- → LC-MS/MS detection of peroxynitrite-derived 3-nitrotyrosine in rat microvessels(2000)63 cited
- → Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1 H -pyrazolo-[3,4- b ]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator(2014)51 cited
- → Tandem Aldol-Cyclization Sequence for the Construction of Cyclic Ethers. The Formation of Substituted Tetrahydrofurans(1994)46 cited